Akari Therapeutics PLC (AKTX) Stock Price Up 10.9%
Akari Therapeutics PLC (NASDAQ:AKTX)’s share price rose 10.9% during trading on Wednesday . The stock traded as high as $8.00 and last traded at $6.49. Approximately 992,054 shares changed hands during mid-day trading, an increase of 1,405% from the average daily volume of 65,930 shares. The stock had previously closed at $5.85.
AKTX has been the topic of several recent analyst reports. Zacks Investment Research lowered Akari Therapeutics PLC from a “strong-buy” rating to a “hold” rating in a report on Tuesday, May 23rd. Chardan Capital raised Akari Therapeutics PLC from a “sell” rating to a “neutral” rating and dropped their target price for the company from $6.50 to $6.00 in a report on Wednesday, May 31st. Canaccord Genuity reissued a “buy” rating and issued a $15.00 target price (down previously from $33.00) on shares of Akari Therapeutics PLC in a report on Monday, June 26th. William Blair reissued an “outperform” rating on shares of Akari Therapeutics PLC in a report on Tuesday, July 4th. Finally, ValuEngine raised Akari Therapeutics PLC from a “strong sell” rating to a “sell” rating in a report on Monday. One research analyst has rated the stock with a sell rating, one has issued a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. Akari Therapeutics PLC has a consensus rating of “Buy” and an average price target of $7.17.
The stock has a 50-day moving average of $3.99 and a 200 day moving average of $7.26. The stock’s market cap is $76.43 million.
An institutional investor recently bought a new position in Akari Therapeutics PLC stock. Hikari Power Ltd bought a new position in Akari Therapeutics PLC (NASDAQ:AKTX) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 60,012 shares of the biopharmaceutical company’s stock, valued at approximately $277,000. Hikari Power Ltd owned about 0.51% of Akari Therapeutics PLC as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 26.85% of the company’s stock.
Akari Therapeutics PLC Company Profile
Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome.
Receive News & Stock Ratings for Akari Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics PLC and related stocks with our FREE daily email newsletter.